Anti-CD19 CAR/NFAT (Luciferase) Reporter Jurkat Cell Line (CD19 SCFV-CD28-4-1BB-CD3ζ) is a stable cell line expressing an anti-CD19 CAR and an NFAT-dependent luciferase reporter. The reporter cell line has been validated for anti- CD19 expression by flow cytometry, and for luciferase reporter activation by target cells, including the CD19 CHO cell line. Anti-CD19 CAR consists of the anti-CD19 scFv linked to 3rd generation CAR containing the CD28, 4-1BB co-stimulatory domains and the CD3ζ signaling domain.

The cell line can be used for primary screening and functional validation of anti-CD19 CAR construct and lentivirus before testing is performed in primary T cells.

Figure 1: Lenti-vector used to generate anti-CD19 CAR lentivirus.

Figure 2. Schematic of anti-CD19 CAR.
Anti-CD19 (scFv) is linked to the 3rd generation CAR with CD28 transmembrane and costimulatory domains, 4-1BB, and CD3ζ components.

Purchase of this cell line is for research purposes only; commercial use requires a separate license. View the full terms and conditions.